Phathom Pharmaceuticals (PHAT) Return on Sales (2023 - 2026)

Phathom Pharmaceuticals (PHAT) has 4 years of Return on Sales data on file, last reported at 0.01% in Q1 2026.

• On a quarterly basis, Return on Sales rose 2.0% year-over-year to 0.01% in Q1 2026; TTM through Mar 2026 was 0.01%, a 4.0% increase from a year earlier, with the FY2025 full-year figure at 0.01%, up 8.0% from the prior year.
• Return on Sales for Q1 2026 stood at 0.01%, down from 0.0% in the prior quarter.
• Over the last five years, Return on Sales for PHAT reached as high as 0.0% in Q4 2025 and fell as low as 1.47% in Q4 2023.
• Historically, Return on Sales has averaged 0.22% across 4 years, with a median of 0.03% in 2024.
• Across the five-year window, Return on Sales soared 145 bps in 2024 and grew 2 bps in 2025, its largest moves.
• Year by year, Return on Sales stood at 1.47% in 2023, then soared by 98 bps to 0.03% in 2024, then surged by 85 bps to 0.0% in 2025, then plunged by 124 bps to 0.01% in 2026.
• Per Business Quant data, the three most recent Return on Sales figures were 0.01% in Q1 2026, 0.0% in Q4 2025, and 0.01% in Q3 2025.